Investor Relations

GABY Announces Leave of Absence for Current CEO and Appointment of Interim CEO

May 1, 2023

GABY Reports Fourth Quarter and Fiscal Year End 2022 Results

May 1, 2023

GABY Inc. Announces a Strategic Acquisition of Highly Regarded and Well Established CBD Brands: Hempfusion(TM), Sagely Naturalstm and Apothecanna(TM)

April 28, 2023

GABY Announces Restructuring of its Debt

April 25, 2023

GABY Reports Third Quarter Results for 2022

November 29, 2022

GABY Reports Second Quarter Results for 2022

August 29, 2022

GABY Reports First Quarter Results for 2022

June 20, 2022

GABY Reports Fourth Quarter and Fiscal Year End 2021 Results

June 16, 2022

CEO of GABY Inc. to Present on GABY’s Strategy” Live at VirtualInvestorConferences.com June 7th

June 6, 2022

GABY Inc. Reflects on Numerous Operational Improvements and Provides Estimated Financial Results for 2021 Fiscal Year

May 23, 2022

GABY Inc’s Mankind Dispensary Celebrates One Million Shoppers with a Huge Customer Appreciation Event March 24-27, 2022

March 23, 2022

GABY Inc Announces the Appointment of Paul Stacey to the Role of Senior Vice-President Finance and Chief Financial Officer

March 6, 2022

GABY Inc Announces Improved Access to Shares for Investors via Recent DTC Eligibility Approval

January 5, 2022

GABY Inc. Reports Solid Q3 2021 Revenue of $9.5MM with Record Gross Profit Margin of 39%

November 24, 2021

GABY Inc. Announces the Appointment of Founder and CEO Margot Micallef to the University of California, Santa Barbara, Women in Leadership Executive Program Advisory Board

November 15, 2021